Atara Shareholder Lawsuit Claims Cell Therapy Approval Prospects Were Overstated

Atara told investors it was on the verge of a breakthrough. A first of its kind cancer therapy. Strong data. FDA approval in sight.

But behind the scenes, serious problems were building.

In May 2024, Atara submitted its FDA application, claiming promising trial results and a smooth path forward. By July, the FDA granted priority review. Executives kept saying the application was on track for approval.

Then January 2025 hit. The FDA rejected the application, pointing to manufacturing issues. The stock dropped about 40% in a single day. Days later, regulators placed a clinical hold, pausing new trial enrollment.

Atara maintained the issues could be addressed and resubmitted. But in January 2026, the FDA rejected it again, this time saying the trial itself was flawed. The stock collapsed nearly 57%.

Investors were stunned.

Now, more investors are joining the lawsuit.